Prosecution Insights
Last updated: November 04, 2026
Application No. 17/623,576

LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE

Non-Final OA §103
Filed
Dec 28, 2021
Priority
Jun 28, 2019 — provisional 62/868,134 +2 more
Examiner
KASSA, TIGABU
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dynamic Biologics Inc.
OA Round
3 (Non-Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
64%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
266 granted / 726 resolved
-23.4% vs TC avg
Strong +28% interview lift
Without
With
+27.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
79 currently pending
Career history
804
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
64.9%
+24.9% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
15.6%
-24.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 726 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09 July 2026 has been entered. Formal Matters Applicant’s claim amendments and arguments in the reply filed on 09 July 2026 are acknowledged and have been fully considered due to the entered request for continued examination. Claims 1, 3-20 and 24-25 are pending. Claims 1 and 24-25 are under consideration in the instant office action. Claims 3-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention and/or species, there being no allowable generic or linking claims. Claims 2 and 21-23 are canceled. Withdrawn Objections/Rejections Rejections and/or objections not reiterated from the previous office actions are hereby withdrawn as are those rejections and/or objections expressly stated to be withdrawn. Moot Arguments Applicants’ arguments with respect to claim(s) 1 and 24-25 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. New Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 and 24-25 are newly rejected under 35 U.S.C. 103 as being unpatentable over Kaiser (U.S. Patent No. 3,859,331) in view of Choubey (Development and evaluation of PEGylated Enoxaparin: A novel approach for enhanced anti-Xa activity,” Bioorganic Chemistry 54 (2014), 1–6). Applicants’ claims Applicants claim a compound of formula I: PNG media_image1.png 792 794 media_image1.png Greyscale Elected Species: Applicant elected the compound of Formula I where: PNG media_image2.png 78 727 media_image2.png Greyscale The instant claim is examined to the extent it reads on the elected species wherein R1 is polyethylene glycol, specifically PEG2000; R2 is hydrogen; and R3 and R4 are each –C(=O)CH2CH3 (propionyl). Determination of the Scope and Content of the Prior Art (MPEP 2141.01) Kaiser teaches it has been found that compounds of the formula PNG media_image3.png 782 326 media_image3.png Greyscale Kaiser teaches O,O′-diesters of L-DOPA and L-DOPA esters useful, inter alia, as anti-Parkinson agents (see abstract). Kaiser et al. expressly state that its contemplated alkanoyl groups include acetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl, and isobutyryl (see column 2, lines 6-26). Kaiser further teaches that the disclosed DOPA derivatives possess anti-Parkinson properties and may be formulated and administered as medicaments. More particularly, Example 10 teaches preparation of an O,O′-dipropionyl-L-DOPA derivative. Kaiser reacts N-carbobenzoxy-L-DOPA methyl ester with propionyl chloride to produce N-carbobenzoxy-O,O′-dipropionyl-L-DOPA methyl ester. Kaiser subsequently removes the N-protecting group. Example 29 expressly identifies O,O′-dipropionyl-L-DOPA methyl ester hydrochloride among the resulting products. Moreover, Kaiser expressly claims the species. Claim 14 recites: “The compound of claim 12 wherein said compound is O,O′-dipropionyl-L-dopa methyl ester.” Accordingly, Kaiser teaches the presently elected L-DOPA stereochemical core wherein the amino substituent corresponding to R2 is hydrogen and both catechol oxygen substituents corresponding to R3 and R4 are propionyl groups, i.e., –C(=O)CH2CH3. Ascertainment of the Difference Between Scope of the Prior Art and the Claims (MPEP 2141.02) Kaiser therefore teaches a compound corresponding structurally to the elected species except that the carboxyl group of the L-DOPA moiety is present as a methyl ester, rather than being esterified with the claimed PEG2000 polymeric moiety. Kaiser does not specifically teach esterification of the DOPA carboxyl group with PEG2000. This deficiency is cured by the teachings of Choubey. Choubey teaches the preparation of a pharmaceutical polymer conjugate by esterifying the carboxyl groups of a drug with the hydroxyl group of mPEG2000. Specifically, Choubey reports preparation of PEGylated enoxaparin using poly(ethylene glycol) methyl ether having a molecular weight of 2000 (mPEG2000). Choubey on p. 2, “Results and discussion,” states that P-ENX was synthesized by: esterification of the carboxyl groups of the ENX moiety with the hydroxyl group of mPEG using EDAC as a carbodiimide coupling agent and DMAP as a catalyst. Choubey further reports that the free-acid form of enoxaparin was conjugated with mPEG2000 by formation of an ester linkage using EDAC and catalytic DMAP. The FTIR analysis showed the carbonyl stretching peak shifting from 1622 cm⁻¹ to 1633 cm⁻¹, which Choubey identifies as indicating formation of the ester bond. Choubey teaches under Materials used (p. 5) specifically identifies poly(ethylene glycol) methyl ether (mPEG 2000) among the materials employed. Choubey under “PEGylation of ENX,” on p. 5, provide the actual reaction conditions. A solution containing mPEG2000 and EDAC in DMF was treated with DMAP followed by enoxaparin, and the mixture was refluxed for 12 hours. Most significantly, Figure 8, p. 5, depicts the reaction of enoxaparin free acid with mPEG2000/EDAC and DMAP to form the enoxaparin-PEG conjugate. Thus, Choubey expressly demonstrates that the terminal hydroxyl functionality of mPEG2000 can be used to esterify a pharmaceutical carboxylic-acid functionality to produce a: Drug–C(=O)–O–PEG2000 conjugate. Finding of Prima Facie Obviousness Rational and Motivation (MPEP 2142-2143) It would have been prima facie obvious to a person of ordinary skill before the effective filing date of the instant invention to modify the O,O′-dipropionyl-L-DOPA compound taught by Kaiser by replacing the alcohol-derived methyl moiety of Kaiser’s L-DOPA carboxyl ester with an mPEG2000-derived polymeric ester moiety, as taught by Choubey. Kaiser expressly teaches that the carboxyl functionality of its DOPA derivatives is amenable to esterification and teaches preparation of corresponding esters using alcohols. Choubey, in turn, expressly teaches that a pharmaceutical carboxylic-acid functionality may be esterified with the hydroxyl functionality of mPEG2000, thereby providing the corresponding PEG2000 ester conjugate. One of ordinary skill therefore would have recognized Choubey’s hydroxyl-terminated mPEG2000 as a known polymeric alcohol suitable for use as an ester-forming moiety at the carboxyl functionality that Kaiser already teaches may be esterified. The skilled artisan also would have had an express pharmaceutical reason for making the modification. Choubey teaches in the introduction that PEGylation was known to provide therapeutic agents with extended circulating half-life, increased stability, and improved in-vivo bioactivity. Choubey specifically undertook PEGylation to extend the duration of drug action and thereby reduce administration frequency. The results reported by Choubey confirm the recognized benefit. As shown in Table 3 and Figures 6–7, PEGylated enoxaparin exhibited a half-life of approximately 7.00 h compared with 2.61 h for unmodified enoxaparin and an AUC of approximately 147.65 compared with 35.64 μg·mL⁻¹·h, respectively. Choubey characterizes these results as approximately a three-fold increase in half-life and approximately a four-fold increase in AUC. Choubey concludes on p. 6 that PEGylation with mPEG2000 through an ester linkage may be adopted to enhance drug half-life and develop a long-acting formulation having the potential for decreased dosing frequency. Accordingly, one of ordinary skill seeking to modify Kaiser’s anti-Parkinson L-DOPA ester to obtain a polymer-conjugated pharmaceutical derivative having prolonged systemic exposure would have been motivated to employ the mPEG2000 ester-forming approach expressly taught by Choubey. One of ordinary skill in the art would also have had a reasonable expectation of successfully making the proposed compound. Kaiser establishes that the L-DOPA carboxyl functionality can be esterified with an alcohol to form corresponding DOPA esters. Choubey independently demonstrates successful esterification of pharmaceutical carboxyl groups with the terminal hydroxyl group of mPEG2000 using conventional EDAC/DMAP carbodiimide coupling chemistry. Choubey does not merely propose such PEGylation; it actually performs the reaction, isolates the conjugate, and characterizes the product by FTIR, 1H NMR, and MALDI. Figure 8 expressly depicts the resulting carboxylate-PEG ester connectivity. Choubey further reports that MALDI analysis of mPEG2000 provided Mn and Mw values of approximately 1984.9 and 2021.9, respectively, confirming use of the PEG2000 polymer. Thus, although Kaiser and Choubey concern different pharmaceutical active agents, Choubey is relied upon for the established chemical teaching that the hydroxyl group of mPEG2000 is capable of esterification with a pharmaceutical carboxyl group using conventional coupling chemistry. Kaiser independently establishes that the corresponding L-DOPA carboxyl group is itself amenable to esterification. The combined teachings therefore would have provided a reasonable expectation of success that mPEG2000 could be coupled through its hydroxyl functionality to the L-DOPA carboxyl group to provide the claimed polymeric ester. The resulting compound would correspond to the elected species wherein R1 is PEG2000, R2 is hydrogen, and R3 and R4 are each –C(=O)CH2CH3. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art before the effective filing date of the instant invention, as evidenced by the references, especially in the absence of evidence to the contrary. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIGABU KASSA whose telephone number is (571)270-5867. The examiner can normally be reached on 8 AM-5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIGABU KASSA/Primary Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Dec 28, 2021
Application Filed
Apr 23, 2025
Non-Final Rejection mailed — §103
Oct 23, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §103
Jul 09, 2026
Request for Continued Examination
Jul 10, 2026
Response after Non-Final Action
Sep 25, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778898
THREE-DIMENSIONAL PRINTED STRUCTURAL SILOXANES HAVING CONTROLLED DRUG RELEASE
7y 7m to grant Granted Nov 03, 2026
Patent 12778889
TREATMENT AGENT
2y 11m to grant Granted Nov 03, 2026
Patent 12778859
ANHYDROUS ANTIPERSPIRANT AEROSOL COMPOSITION
2y 7m to grant Granted Nov 03, 2026
Patent 12766171
LONG-TERM STABLE LIVE FECAL MICROBIOTA COMPOSITION
5y 0m to grant Granted Oct 20, 2026
Patent 12685714
MICROSPHERE FORMULATIONS COMPRISING KETAMINE AND METHODS FOR MAKING AND USING THE SAME
3y 6m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
64%
With Interview (+27.7%)
4y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 726 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month